Adaptimmune Therapeutics PLC (ADAP) Upgraded at Zacks Investment Research
Adaptimmune Therapeutics PLC (NASDAQ:ADAP) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Monday.
According to Zacks, “Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in Abingdon, United Kingdom. “
Separately, Raymond James Financial Inc. assumed coverage on Adaptimmune Therapeutics PLC in a research report on Friday, September 30th. They set an “outperform” rating and a $16.00 price target on the stock. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $15.95.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/10/adaptimmune-therapeutics-plc-adap-upgraded-at-zacks-investment-research.html
Shares of Adaptimmune Therapeutics PLC (NASDAQ:ADAP) traded up 3.91% during midday trading on Monday, reaching $6.65. The company had a trading volume of 169,014 shares. The company’s market capitalization is $470.72 million. The company has a 50 day moving average of $7.06 and a 200 day moving average of $8.43. Adaptimmune Therapeutics PLC has a one year low of $6.19 and a one year high of $14.78.
Adaptimmune Therapeutics PLC (NASDAQ:ADAP) last issued its quarterly earnings data on Monday, August 8th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.21) by $0.16. Adaptimmune Therapeutics PLC had a negative return on equity of 21.36% and a negative net margin of 427.33%. Analysts predict that Adaptimmune Therapeutics PLC will post ($1.09) EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently made changes to their positions in ADAP. Adage Capital Partners GP L.L.C. boosted its position in shares of Adaptimmune Therapeutics PLC by 34.8% in the second quarter. Adage Capital Partners GP L.L.C. now owns 1,550,000 shares of the company’s stock worth $12,633,000 after buying an additional 400,000 shares during the period. Rathbone Brothers plc boosted its position in shares of Adaptimmune Therapeutics PLC by 124.7% in the second quarter. Rathbone Brothers plc now owns 450,525 shares of the company’s stock worth $3,672,000 after buying an additional 250,000 shares during the period. Opaleye Management Inc. bought a new position in shares of Adaptimmune Therapeutics PLC during the first quarter worth about $1,425,000. New Leaf Venture Partners L.L.C. bought a new position in shares of Adaptimmune Therapeutics PLC during the second quarter worth about $1,035,000. Finally, Renaissance Technologies LLC boosted its position in shares of Adaptimmune Therapeutics PLC by 286.3% in the first quarter. Renaissance Technologies LLC now owns 113,200 shares of the company’s stock worth $920,000 after buying an additional 83,900 shares during the period. 45.11% of the stock is currently owned by hedge funds and other institutional investors.
About Adaptimmune Therapeutics PLC
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.